If You Invested in Fifty 1 Labs Inc (FITY)

Fifty 1 Labs, Inc. (OTC: FITY) is a Nevada-based holding company in the financial markets that focuses its operating activities on health, wellness, and biotechnology applications powered by artificial intelligence. While classified in the financial services sector under credit services, the company describes itself as an applied life sciences and wellness business that uses AI, real‑world evidence, and functional medicine approaches to advance drug repurposing and personalized health solutions.

Through its operating efforts and subsidiaries, including the former subsidiary Fifty1 AI Labs, Fifty 1 Labs concentrates on AI‑driven drug repurposing, precision medicine, and functional and preventative medicine. The company highlights work in areas such as energy, cognition, immune function, healthy aging, and broader wellness, using AI to identify new therapeutic applications for existing, safe, off‑patent compounds. This approach is intended to shorten development timelines and support more cost‑effective therapies.

Business focus and operating themes

According to company communications, Fifty 1 Labs positions its activities around several core themes:

• AI‑driven drug repurposing: Using proprietary AI modeling, real‑world clinical data, and literature‑derived case reports to uncover new uses for existing medicines and compounds.
• Functional and preventative medicine: Targeting high‑growth markets in functional medicine and wellness by applying AI insights to conditions related to fatigue, cognition, metabolic health, sleep, immune function, and healthy aging.
• Real‑world evidence and oncology data: Developing technical frameworks and analytics for oncology real‑world evidence, including work on transportability methods to make data actionable across borders.
• AI‑enhanced clinical data analytics: Collaborating with AI technology partners to structure and analyze clinical narratives at scale for therapeutic development and outcomes research.

Fifty 1 Labs has described itself as a company that integrates AI with clinical and epidemiological methods to support drug repurposing and personalized wellness. Its communications emphasize the use of large‑scale clinical, genomic, and patient outcome data, as well as real‑world case reports, to inform therapeutic strategies.

Role of Fifty1 AI Labs and divestment

Fifty1 AI Labs has been a key operating vehicle for the group’s AI‑driven initiatives. It has been described as a subsidiary of Fifty 1 Labs, Inc. focused on repurposing safe, off‑patent compounds and using AI to unlock new potential in proven medicines. The company has highlighted work in musculoskeletal health, pain management, perioperative outcomes, sports medicine, surgical safety, clinical care outcomes, and peptides, as well as broader personalized wellness and health research.

Fifty1 AI Labs has also been associated with AI‑driven oncology real‑world evidence frameworks, including a published technical primer on transportability methods in oncology data, and with large‑scale studies in sickle cell disease using real‑world patient data. In addition, it has been linked to partnerships in antiviral drug repurposing and functional medicine initiatives.

Fifty 1 Labs, Inc. has stated that it has divested from Fifty1 AI Labs Inc. as of December 3, 2025. Following this divestment, the company has clarified that Fifty1 Labs and Fifty1 AI Labs are separate entities, and that there is no overlap in work, leadership, funding, or affiliation with certain third parties referenced in prior communications.

Collaborations and technical initiatives

Company disclosures describe several collaborations and initiatives involving Fifty1 AI Labs while it was associated with Fifty 1 Labs, including:

• Clinical data analytics and AI tools: A history of collaboration with BioSpark AI Technologies Inc., a Vancouver‑based company engaged in developing and commercializing patented AI systems for clinical data extraction, structuring, and real‑time analysis. This collaboration has been used to transform unstructured case reports into structured, queryable treatment‑outcome pathways.
• Oncology real‑world evidence: Development and publication of a technical primer on transportability methods in oncology real‑world evidence, describing how advanced statistical and AI‑driven frameworks can make non‑local data actionable for health technology assessments and regulatory decision‑making.
• Sickle cell disease research: Completion of what the company describes as a large and comprehensive study of sickle cell disease, using real‑world patient data in collaboration with academic and global health partners, with the goal of informing gene‑based therapies and repurposed medicines.
• Pandemic preparedness and antiviral repurposing: A partnership between Fifty1 AI Labs and ViRx@Stanford under the "BE READI!" initiative, focused on using AI to repurpose existing drugs into antiviral therapies and support biosecurity and pandemic preparedness.

These initiatives reflect the company’s emphasis on combining AI, advanced statistics, and clinical research methods to generate evidence for new therapeutic applications.

Capital markets and corporate positioning

Fifty 1 Labs, Inc. trades on the over‑the‑counter market under the symbol FITY. The company has announced that it engaged a Public Company Accounting Oversight Board (PCAOB)‑registered auditing firm to audit its financial statements for two fiscal years, describing this as part of a plan to seek an uplisting of its shares to the OTCQB Venture Market. The company has presented this step as aligned with goals related to transparency, compliance, and corporate governance standards associated with that marketplace.

In communications with shareholders, Fifty 1 Labs has described a growth strategy centered on AI‑powered drug repurposing, functional medicine, and potential biotech‑related acquisitions. It has also emphasized alignment between management and shareholders through references to personal investments and compensation structures, as described in its public statements.

Clarifications regarding collaborations

Fifty 1 Labs, Inc. has issued a clarification regarding prior communications about a potential collaboration with LUNR Aerospace. The company has stated that no formal partnership or collaboration has ever been formed between Fifty1 Labs, Inc. (or its subsidiary Fifty1 AI Labs) and LUNR Aerospace, and that there is no current intent to do so. It has also stated that, following the resignation of a prior executive and the divestment from Fifty1 AI Labs Inc., there is no common ownership, management, or directors between Fifty1 Labs and LUNR Aerospace, and no overlap in work, leadership, funding, or affiliation.

Investor and research orientation

Across its public communications, Fifty 1 Labs presents itself as oriented toward investors and partners interested in AI‑enabled drug repurposing, functional medicine, and biotech‑related innovation. The company’s descriptions highlight:

• Use of AI and machine learning for trial design, implementation, and evidence generation.
• Emphasis on evidence‑based health research, clinical trial methodology, and outcome measurement.
• Focus on repurposing off‑patent compounds and developing personalized interventions in wellness and preventative care.
• Engagement with academic, clinical, and global health collaborators to support its research programs.

According to its statements, these elements are intended to differentiate its approach in AI‑driven healthcare, functional medicine, and drug repurposing.

FAQs about Fifty 1 Labs, Inc. (FITY)